English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/161797
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma

Other TitlesmiRNA contribution to BRAF inhibitor melanoma resistance
AuthorsDíaz-Martínez, Marta; Benito-Jardón, Lucía ; Alonso, Lola; Koetz-Ploch, Lisa; Hernando, Eva; Teixidó, Joaquín
BRAF inhibitor
MAP kinases
Issue Date15-Feb-2018
PublisherAmerican Association for Cancer Research
CitationCancer Res 78(4):1017-1030 (2018)
AbstractMelanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic benefits but the common emergence of drug resistance remains a challenge. We generated A375 melanoma cells resistant to vemurafenib with the goal of investigating changes in miRNA expression patterns that might contribute to resistance. Increased expression of miR-204-5p and miR-211-5p occurring in vemurafenib-resistant cells was determined to impact vemurafenib response. Their expression was rapidly affected by vemurafenib treatment through RNA stabilization. Similar effects were elicited by MEK and ERK inhibitors but not AKT or Rac inhibitors. Ectopic expression of both miRNA in drug-naïve human melanoma cells was sufficient to confer vemurafenib resistance and more robust tumor growth in vivo Conversely, silencing their expression in resistant cells inhibited cell growth. Joint overexpression of miR-204-5p and miR-211-5p durably stimulated Ras and MAPK upregulation after vemurafenib exposure. Overall, our findings show how upregulation of miR-204-5p and miR-211-5p following vemurafenib treatment enables the emergence of resistance, with potential implications for mechanism-based strategies to improve vemurafenib responses.Significance: Identification of miRNAs that enable resistance to BRAF inhibitors in melanoma suggests a mechanism-based strategy to limit resistance and improve clinical outcomes.
Description42 p.-7 fig.
Publisher version (URL)http://dx.doi.org/10.1158/0008-5472.CAN-17-1318
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Díaz-Martínez_Cancer Research_2018.pdfPostprint2,17 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.